{{org_field_logo}}
{{org_field_name}}
Registration Number: {{org_field_registration_no}}
Syringe Driver Guidance and Best Practices for Nurses Policy
1. Purpose
The purpose of this policy is to ensure that continuous subcutaneous infusions delivered by a syringe pump or syringe driver are prescribed, prepared, administered, monitored and discontinued safely and appropriately at {{org_field_name}}.
Syringe pumps must only be used where their use is clinically indicated and where the resident’s assessed needs, wishes, preferences, personal outcomes and clinical circumstances have been considered. Care must be provided in accordance with the resident’s personal plan and any relevant clinical or end-of-life care plan.
This policy supports compliance with:
- the Regulation and Inspection of Social Care (Wales) Act 2016;
- the Regulated Services (Service Providers and Responsible Individuals) (Wales) Regulations 2017, as amended, including Regulation 21 relating to standards of care and support, Regulation 34 relating to suitably qualified and competent staff, Regulation 36 relating to staff support and development, Regulation 57 relating to health and safety, Regulation 58 relating to medicines, Regulation 59 relating to records and Regulation 60 relating to notifications;
- the Mental Capacity Act 2005 and the Mental Capacity Act 2005 Code of Practice;
- applicable medicines legislation, including the Human Medicines Regulations 2012 and legislation governing controlled drugs where controlled drugs are prescribed;
- the Nursing and Midwifery Council Code and applicable professional standards;
- current Welsh national guidance for palliative and end-of-life care;
- current Medicines and Healthcare products Regulatory Agency safety information, Field Safety Notices and manufacturer’s instructions relating to the syringe pump being used.
The service provider must ensure that medicines are managed safely and that registered nurses who use syringe pumps have the knowledge, skills and competence required for the equipment, medicines and clinical circumstances involved.
2. Scope
This policy applies to:
- Registered nurses at {{org_field_name}} who are responsible for the setup, monitoring, and discontinuation of syringe drivers.
- Senior management and clinical leads, ensuring oversight and governance of syringe driver use.
- Medical professionals and external prescribers, ensuring collaborative care in medication management.
- Residents and families, ensuring informed consent, person-centred care, and family engagement in decision-making.
3. Managing Syringe Drivers Efficiently
3.1 Indications for Syringe Driver Use
Syringe drivers are used when oral or transdermal medication administration is ineffective or impractical. Indications include:
- End-of-life care, ensuring continuous pain relief and symptom management.
- Severe nausea or vomiting, preventing effective oral medication absorption.
- Dysphagia (swallowing difficulties), common in advanced dementia, neurological disorders, or cancer care.
- Uncontrolled pain, requiring continuous opioid infusion for comfort.
Syringe drivers must only be used following a clinical assessment by a prescriber, with a clear rationale documented in the resident’s care plan.
3.2 Prescribing and Authorisation
All medicines administered by continuous subcutaneous infusion must be prescribed by an appropriately authorised prescriber and the prescription must constitute a clear, valid and unambiguous direction for administration.
The prescription must include, as applicable:
- the resident’s identifying details;
- the approved name of each medicine;
- the dose of each medicine to be administered over the prescribed infusion period;
- the prescribed route;
- the prescribed diluent and volume, where applicable;
- the intended infusion duration;
- the date and time of prescribing;
- any relevant maximum dose or dose-range instructions;
- appropriate instructions for breakthrough or ‘as required’ medicines;
- the prescriber’s identification and authorisation;
- any additional instructions necessary for safe administration.
Before preparing or administering the infusion, the registered nurse must ensure that:
- the prescription is valid, legible and unambiguous;
- the medicine, dose, route, diluent and prescribed infusion period are appropriate to the prescription;
- allergies and relevant sensitivities have been checked;
- the medicines to be combined are compatible at the prescribed concentrations and with the prescribed diluent;
- the prescription corresponds with the resident’s current clinical condition and care plan;
- any dose calculations are correct;
- the resident has been appropriately assessed and consent or other lawful authority for treatment is established.
Any uncertainty, discrepancy, incomplete direction or concern about the prescription must be clarified with the prescriber or an appropriate pharmacist before administration.
Independent checking must be undertaken where required by applicable legislation, the organisation’s medicines or controlled drugs procedures, local Health Board arrangements or other applicable clinical governance requirements. Where an independent check is required, the identities of the persons undertaking the check must be recorded.
Registered nurses remain professionally accountable for medicines they prepare and administer and must work within their competence and in accordance with the Nursing and Midwifery Council Code.
3.3 Equipment, Safety Checks and Set-up
Only syringe pumps approved for use by {{org_field_name}} and suitable for the intended clinical purpose may be used. The device must be operated strictly in accordance with the current manufacturer’s instructions for use, applicable local clinical guidance and any current Medicines and Healthcare products Regulatory Agency safety communication or manufacturer Field Safety Notice.
Before a syringe pump is used, the registered nurse must ensure that:
- they have been trained and assessed as competent to use the particular make and model of syringe pump;
- the device is within its required servicing and maintenance period;
- there is no visible damage, contamination, defect or other indication that the device may be unsafe;
- all relevant pre-use checks specified by the manufacturer have been completed;
- the correct syringe type and size approved for the device are being used;
- the syringe and extension set are correctly fitted;
- the extension set is not kinked, occluded, damaged or disconnected;
- the battery has sufficient capacity for the intended infusion, in accordance with the manufacturer’s instructions;
- the programmed infusion corresponds with the prescription;
- the infusion site is clinically appropriate;
- the device is protected from circumstances that could adversely affect its operation, including fluid ingress, excessive heat, direct sunlight or inappropriate accessories, as specified by the manufacturer.
A luer-lock syringe and compatible extension set must be used where specified by the device manufacturer and applicable clinical guidance.
The infusion line must be prepared and primed in accordance with the manufacturer’s instructions, the prescribed therapy and applicable clinical guidance.
Following set-up, the nurse must confirm that the infusion has commenced correctly and record the required details on the appropriate medication administration and syringe pump monitoring documentation.
The record must include, as applicable:
- date and time commenced;
- medicines and doses administered;
- prescribed diluent and total volume;
- syringe size;
- prescribed duration and/or programmed rate;
- infusion site;
- device identification where required by local procedure;
- the identity of the nurse administering the infusion and any required checker.
Where a Medicines and Healthcare products Regulatory Agency alert or manufacturer Field Safety Notice applies to equipment used by the service, the service must establish whether its devices are affected, implement the required actions and retain evidence of the action taken.
A syringe pump must not be used where there is reason to believe that it is defective, damaged, overdue for required servicing or otherwise unsafe. It must be removed from clinical use, clearly identified as unavailable for use and managed in accordance with the organisation’s medical device procedure.
3.4 Monitoring and Troubleshooting
The resident, infusion site, infusion solution, extension line and syringe pump must be monitored at a frequency appropriate to the resident’s clinical condition, the care setting, the prescribed therapy, current national or local clinical guidance and the manufacturer’s instructions for the device.
The pump must also be checked promptly after initial set-up, reloading, reprogramming or re-siting, and whenever an alarm occurs, the resident’s symptoms change or there is concern that the infusion is not progressing as intended.
Each monitoring check must include, as applicable:
- confirmation that the correct resident is receiving the prescribed infusion;
- assessment of the resident’s symptoms, comfort and response to treatment;
- assessment for adverse effects, excessive sedation, toxicity or deterioration requiring clinical review;
- inspection of the infusion site for pain, redness, inflammation, swelling, leakage, bleeding, displacement, induration or other signs of site failure;
- confirmation that the syringe and extension line remain correctly connected and secure;
- inspection of the syringe contents and line for precipitation, cloudiness, discolouration, crystallisation, particles or other evidence of incompatibility;
- confirmation that the syringe pump is operating and the infusion is progressing as expected;
- review of the volume infused and volume remaining where applicable;
- confirmation that no relevant alarm or warning is present;
- confirmation that the device and battery remain suitable for continued operation.
The resident’s symptoms must be reviewed regularly and, for a person recognised as being in the last days of life, at least daily and more frequently where clinically required. A prescriber or specialist palliative care professional must be contacted where symptoms remain uncontrolled, repeated breakthrough medication is required, adverse effects occur or the prescribed regimen may require adjustment.
Pump alarms must be responded to promptly in accordance with the manufacturer’s instructions. Nurses must not rely solely on the alarm system to identify an interruption or under-infusion.
Where an occlusion or interruption is suspected, the nurse must assess the complete infusion system, including the syringe, extension set, connections and infusion site, and follow the manufacturer’s troubleshooting instructions. The nurse must not make an unauthorised alteration to the prescribed dose or infusion parameters.
Where the problem cannot be safely resolved, or where there is concern that the resident has received too much or too little medicine, the infusion must be made safe and appropriate urgent clinical advice obtained. The resident must be monitored for clinical consequences and the event documented and reported in accordance with Section 3.10 of this policy.
All monitoring checks, concerns and actions taken must be recorded contemporaneously.
3.5 Medicine Compatibility, Diluent and Stability
Before two or more medicines are combined in the same syringe for continuous subcutaneous infusion, the registered nurse must establish that the combination is compatible and sufficiently stable for the prescribed infusion period at the concentrations and volume being used.
Compatibility must be checked against a current, recognised specialist palliative care or medicines information source approved by the organisation. Where information is unavailable, conflicting or unclear, advice must be obtained from an appropriate pharmacist, specialist palliative care service or prescriber before the medicines are mixed and administered.
The number of medicines in a syringe must not be determined by an arbitrary numerical limit. The acceptability of a combination must instead be determined by verified compatibility and stability information, prescribed doses and concentrations, the required diluent and volume, the resident’s clinical needs and applicable specialist advice.
The diluent must be prescribed or otherwise clearly authorised in accordance with applicable prescribing arrangements and current clinical guidance. For continuous subcutaneous infusions used in palliative and end-of-life care, water for injection should normally be used where this is recommended by current Welsh guidance and is compatible with the prescribed medicines. Sodium chloride 0.9% or another diluent must only be used where appropriate for the prescribed medicine combination and supported by current compatibility information or specialist advice.
The prepared infusion must be inspected at set-up and during subsequent monitoring for:
- precipitation;
- crystallisation;
- cloudiness;
- discolouration;
- separation;
- particles;
- other visible changes that may indicate incompatibility or instability.
Where physical incompatibility or instability is observed or reasonably suspected, the affected infusion must not continue to be administered without clinical assessment. The nurse must take appropriate action to protect the resident, obtain advice from a pharmacist, prescriber or specialist palliative care professional, and arrange an alternative prescription or preparation where required.
Any medicine incompatibility, suspected incompatibility and action taken must be documented in the resident’s records.
3.6 Prevention and Management of Complications
Registered nurses must remain alert to complications associated with continuous subcutaneous infusion and take prompt action where a problem is identified.
Potential complications include:
- pain, redness, inflammation, swelling, induration, bleeding or leakage at the infusion site;
- displacement or accidental disconnection of the cannula or extension line;
- occlusion;
- interruption or under-infusion;
- unintended over-infusion;
- medicine incompatibility or precipitation;
- device malfunction;
- uncontrolled or breakthrough symptoms;
- adverse medicine effects or excessive sedation.
The infusion site must be selected in accordance with the resident’s clinical condition and current clinical guidance and must be inspected regularly. An infusion site must be changed where clinically indicated, including where there is pain, inflammation, swelling, leakage, displacement, poor absorption or other evidence that the site is unsuitable. Sites must not be changed solely because a fixed period has elapsed unless this is required by the device, cannula manufacturer or applicable local clinical guidance.
Where breakthrough symptoms occur, the nurse must assess the resident, administer prescribed ‘as required’ medication when clinically indicated and authorised, record its administration and evaluate the response. Repeated breakthrough doses, persistent symptoms or a significant change in the resident’s condition must prompt timely review by an appropriate prescriber or specialist palliative care professional.
Any interruption, unexplained discrepancy in the volume delivered, accidental disconnection, suspected over-infusion or under-infusion, device failure or other significant complication must result in an immediate assessment of the resident and the infusion system. Appropriate clinical advice must be obtained and the event must be documented and reported in accordance with the organisation’s incident-reporting arrangements.
3.7 Resident Communication, Consent and Involvement of Representatives
The resident must be given information about the proposed use of a syringe pump in a way that they can understand and which takes account of their communication needs, preferred language and individual circumstances.
The registered nurse and other relevant healthcare professionals must, as appropriate, explain:
- why a syringe pump is being considered;
- how the pump works;
- the intended benefits of treatment;
- the medicines being administered and the symptoms they are intended to manage;
- significant risks or side effects that are relevant to the decision;
- how the pump and infusion site will be monitored;
- whom the resident should tell if they experience discomfort or have concerns.
The resident’s consent must be obtained where they have capacity to make the relevant decision. A resident with capacity has the right to accept or refuse the proposed treatment.
The resident must not be assumed to lack capacity because of age, diagnosis, disability, communication difficulty or because they make a decision that others consider unwise. Where there is reason to doubt capacity, capacity must be assessed in relation to the specific decision in accordance with the Mental Capacity Act 2005.
Where the resident lacks capacity to make the relevant decision, treatment must only proceed where there is lawful authority to do so and the decision is made in accordance with the Mental Capacity Act 2005. The decision-maker must act in the resident’s best interests, take account of the resident’s past and present wishes, feelings, beliefs and values, and consult relevant people as required by the Act.
Family members or friends must not be treated as having authority to consent on the resident’s behalf solely because of their relationship to the resident. Where a person holds a valid and applicable Lasting Power of Attorney for health and welfare, or another person has lawful decision-making authority relevant to the matter, their authority must be verified and respected within its legal scope.
Any valid and applicable advance decision to refuse treatment must be respected.
The resident’s involvement, consent, capacity assessment where required, best-interests decision and involvement of any authorised representative must be documented appropriately.
Families and people important to the resident should be provided with appropriate information and support, subject to the resident’s consent, confidentiality requirements and any lawful authority applying to the decision.
3.8 Documentation and Record-Keeping
Records relating to syringe pump treatment must be accurate, complete, contemporaneous, legible, attributable to the person making the entry and maintained securely in accordance with the organisation’s records management procedures.
The resident’s personal plan and relevant clinical or end-of-life care documentation must identify the resident’s needs in relation to symptom management and continuous subcutaneous infusion where this forms part of their care. The personal plan must be reviewed and revised as necessary when the resident’s needs or treatment change.
The registered nurse must record, as applicable:
- the clinical indication for the syringe pump;
- the prescription under which the infusion is administered;
- each medicine, dose and prescribed diluent;
- total volume and prescribed infusion duration;
- date and time the infusion was commenced;
- syringe size and relevant device details;
- infusion site;
- required independent checks, where applicable;
- monitoring observations;
- the volume infused and/or volume remaining where required by the device or monitoring procedure;
- the condition of the infusion solution, line and site;
- the resident’s symptoms and response to treatment;
- administration and effectiveness of breakthrough medicines;
- adverse effects or complications;
- alarms, interruptions, discrepancies or device problems;
- communication with the prescriber, pharmacist, specialist palliative care service or other healthcare professional;
- any alteration to the prescription;
- date, time and reason for discontinuing the infusion;
- the amount of solution remaining where an infusion is discontinued before completion;
- actions taken following any medicine error, device incident or other concern.
Medicine administration must be recorded on the appropriate medication administration record or other authorised medication documentation.
Where controlled drugs are used, all additional records required by applicable controlled drugs legislation and the organisation’s controlled drugs procedure must also be completed.
Records must be retained and made available in accordance with Regulation 59 and the organisation’s records management policy.
3.9 Syringe Pump Training and Competency Assessment
Only registered nurses who have received appropriate training and have been assessed as competent may independently prepare, set up, administer, monitor, troubleshoot or discontinue a syringe pump.
Training and competency assessment must be relevant to the make and model of syringe pump in use and must include, as applicable:
- indications for continuous subcutaneous infusion;
- safe medicines management;
- prescription interpretation and dose calculations;
- medicine compatibility and stability;
- selection and use of diluents;
- syringe and extension-set selection;
- preparation and priming;
- device programming and set-up;
- appropriate infusion-site selection and assessment;
- monitoring requirements;
- recognition and management of alarms;
- prevention, identification and management of under-infusion and over-infusion;
- recognition of device faults;
- relevant manufacturer instructions;
- applicable Medicines and Healthcare products Regulatory Agency safety communications and Field Safety Notices;
- documentation and incident reporting;
- requirements relating to controlled drugs where applicable;
- professional accountability and escalation of clinical concerns.
Competence must be demonstrated before independent practice and reassessed whenever there is reason to question competence, following a significant change in equipment or procedure, following a relevant incident where retraining is indicated, or at intervals determined through the organisation’s training-needs analysis and clinical governance arrangements.
Where a registered nurse has not used the device for a period sufficient to affect their competence or confidence, they must seek appropriate supervision, refresher training and reassessment before independently managing the device.
The service provider must maintain an up-to-date record of training, competency assessment and any required reassessment.
Registered nurses must work within the limits of their knowledge and competence and must seek appropriate assistance where they are not competent to undertake any aspect of syringe pump management.
3.10 Incident Reporting, External Notifications and Learning
Any medicine error, omission, incorrect rate, incorrect dose, incorrect medicine, device malfunction, suspected over-infusion or under-infusion, interruption of treatment, adverse reaction or other incident associated with a syringe pump must be addressed promptly to protect the resident.
The registered nurse must:
- assess the resident immediately and take appropriate action to secure their safety;
- obtain urgent medical assistance where clinically indicated;
- notify an appropriate prescriber and the Registered Manager or person in charge;
- continue or increase clinical monitoring where required;
- preserve relevant information and equipment where this may be required for investigation;
- make an accurate contemporaneous entry in the resident’s records;
- complete the organisation’s incident reporting documentation.
The Registered Manager or delegated senior person must assess the incident to establish whether any external notification or referral is required.
The service provider must notify Care Inspectorate Wales of any event that meets the notification requirements in Regulation 60 and Schedule 3 of the Regulated Services (Service Providers and Responsible Individuals) (Wales) Regulations 2017, as amended. Required notifications must be made without delay, in writing and in the form or manner required by Care Inspectorate Wales.
Not every medicine error or syringe pump incident is automatically notifiable to Care Inspectorate Wales. Each incident must therefore be assessed against the applicable statutory notification criteria and the reasons for the decision to notify or not notify must be capable of being demonstrated.
Where an incident involving a syringe pump or associated medical device meets the criteria for reporting to the Medicines and Healthcare products Regulatory Agency, it must also be reported through the applicable national medical-device incident reporting route, including the Yellow Card reporting system where appropriate.
Where the incident gives rise to a safeguarding concern, the organisation’s safeguarding policy and the Wales Safeguarding Procedures must be followed without delay.
Where a controlled drug is involved, any additional reporting or investigation requirements arising from controlled drugs legislation, local controlled drug arrangements or the organisation’s controlled drugs procedure must be followed.
The service provider must ensure that incidents and near misses are reviewed to identify causes, themes, trends and necessary improvement actions. Relevant learning must be shared with staff, incorporated into training or procedures where necessary and considered through the service’s medicines audit and quality-assurance arrangements.
4. Responsibilities
4.1 Management Responsibilities
The service provider, Registered Manager and other persons with delegated clinical governance responsibilities must ensure that:
- this policy remains aligned with current legislation, statutory guidance, national clinical guidance and applicable professional standards;
- there are safe systems for the prescribing, preparation, administration, monitoring, recording and disposal of medicines administered through syringe pumps;
- only suitably qualified, trained, skilled and competent registered nurses independently manage syringe pumps;
- competency records are maintained and reviewed;
- sufficient appropriately competent registered nurses are available to meet residents’ assessed nursing needs;
- approved syringe pumps and associated equipment are suitable, maintained, serviced and used in accordance with the manufacturer’s instructions;
- relevant Medicines and Healthcare products Regulatory Agency safety communications and manufacturer Field Safety Notices are identified, assessed and acted upon;
- affected equipment is identified and removed from use where required;
- medicines storage and administration arrangements are regularly audited in accordance with Regulation 58;
- records relating to syringe pump treatment are accurate, complete and securely maintained;
- incidents, medicine errors, near misses and device failures are investigated and used to support learning and improvement;
- statutory notifications are made to Care Inspectorate Wales and other relevant authorities where the applicable notification criteria are met;
- appropriate arrangements are in place for access to prescribers, pharmacy advice, specialist palliative care advice and urgent medical assistance.
4.2 Nursing Responsibilities
Registered nurses involved in syringe pump management are responsible for:
- practising in accordance with the Nursing and Midwifery Council Code and within the limits of their competence;
- ensuring that they have been trained and assessed as competent in the particular syringe pump being used;
- confirming that there is a valid and appropriate prescription before administration;
- checking allergies, medicines, doses, route, diluent, compatibility and prescribed infusion duration before preparing the infusion;
- preparing, setting up and programming the device correctly;
- completing applicable manufacturer pre-use checks;
- monitoring the resident, infusion site, medication solution, line and syringe pump at the required frequency;
- recognising and responding promptly to alarms, deterioration, uncontrolled symptoms, adverse effects, suspected medicine incompatibility and device malfunction;
- maintaining accurate and contemporaneous documentation;
- seeking timely advice from a prescriber, pharmacist, specialist palliative care professional or other appropriate healthcare professional when required;
- respecting the resident’s consent, capacity, wishes and preferences and complying with the Mental Capacity Act 2005 where the resident lacks capacity;
- reporting medicine errors, adverse incidents, near misses and equipment concerns promptly;
- escalating safeguarding concerns in accordance with the organisation’s safeguarding procedure;
- ensuring that defective or potentially unsafe equipment is removed from clinical use and reported in accordance with the organisation’s medical device arrangements.
5. Related Policies
This policy must be read in conjunction with the following {{org_field_name}} policies and procedures, where applicable:
- Medication Management and Administration Policy;
- Controlled Drugs Policy or controlled drugs procedures;
- End-of-Life and Palliative Care Policy;
- Medical Devices and Equipment Management Policy;
- Incident Reporting and Investigation Policy;
- Safeguarding Policy;
- Infection Prevention and Control Policy;
- Mental Capacity Act and Deprivation of Liberty Safeguards Policy;
- Records Management and Confidentiality Policy;
- Staff Training and Competency Policy.
Where there is any inconsistency between this policy and a current legal requirement, national clinical requirement, Medicines and Healthcare products Regulatory Agency safety instruction or manufacturer’s safety instruction, the applicable legal or safety requirement must be followed and the discrepancy escalated to the Registered Manager for immediate review of this policy.
6. Policy Review
This policy will be formally reviewed at least annually and sooner where necessary.
An earlier review must be undertaken where there is:
- a change in relevant legislation or statutory guidance;
- a change in Care Inspectorate Wales requirements;
- new or revised Welsh national clinical guidance relevant to syringe pumps, medicines management or palliative and end-of-life care;
- a relevant Medicines and Healthcare products Regulatory Agency safety communication or manufacturer Field Safety Notice;
- introduction of a new make or model of syringe pump;
- a change to the manufacturer’s instructions for use;
- a significant medicine error, device incident or near miss indicating that the policy may require amendment;
- audit findings showing that existing arrangements are ineffective or unsafe.
The Registered Manager must ensure that any required amendments are implemented promptly and communicated to relevant staff.
The Responsible Individual must have suitable arrangements in place to ensure that this policy and associated procedures remain up to date and that staff have access to, understand and follow the current version.
Responsible Person: {{org_field_registered_manager_first_name}} {{org_field_registered_manager_last_name}}
Reviewed on: {{last_update_date}}
Next Review Date: {{next_review_date}}
Copyright © {{current_year}} – {{org_field_name}}. All rights reserved.